en · de · es · fr · pt
bpc-157-notes.peptides4800.com › Faq › Background, Origin, And Naming — Beginner to Advanced

Background, Origin, And Naming — Beginner to Advanced

By Editorial Desk · published 2025-12-30 · last reviewed 2026-01-29 · Faq

The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.

Background, Origin, and Naming

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

BPC-157 Origin and Structure

Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.

Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.

Bpc-157 at a glance

PropertyValueNotes
Molecular formulaC62H98N16O22Computed for the free peptide
Monoisotopic massApproximately 1419 DaReported values shift with counterion and hydration
Residue count15 amino acidsSequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
OriginFragment of human gastric juice proteinFirst described in early 1990s research reports
Common synonymsBPC 157; PL 14736; bepecinNaming varies across papers and catalogues

Origin and Peptide Identity

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Related pages on this site

BPC-157 Identity and Origin

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.

Stability, Storage, and Analytical Testing

Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.

A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.

Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.

Storage, Handling, and Analytical Verification

Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.

Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.

Background from the literature

== Mechanism of action == Zidesamtinib is a kinase inhibitor that works by blocking ROS1, an abnormal protein that drives some lung cancers to grow, including forms that have become resistant to earlier ROS1 treatments. Zidesamtinib also works on the related protein ALK. In laboratory and animal studies, zidesamtinib stopped cancer cells with ROS1 changes from growing and slowed tumor growth, including tumors in the brain.

=== Kidney involvement === Renal involvement is a key complication of MCTD. Some studies show that it affects around 25% of people and is generally asymptomatic. The most prevalent finding is membranous nephropathy; however, nephrotic range proteinuria may also occur. Tubulointerstitial nephritis, mesangioproliferative glomerulonephritis, and hypertensive episodes resembling scleroderma renal crisis have also been observed.

== Measurement == The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following a 12-hour fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g). The AUC of the test food is divided by the AUC of the standard (either glucose or white bread, giving two different definitions) and multiplied by 100. The average GI value is calculated from data collected in 10 human subjects. Both the standard and test food must contain an equal amount of available carbohydrate. The result gives a relative ranking for each tested food. Foods with carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream tend to have a high GI; foods with carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, tend to have a low GI. A lower glycemic index suggests slower rates of digestion and absorption of the foods' carbohydrates and can also indicate greater extraction from the liver and periphery of the products of carbohydrate digestion. The current validated methods use glucose as the reference food, giving it a glycemic index value of 100 by definition. This has the advantages of being universal and producing maximum GI values of approximately 100. White bread can also be used as a reference food, giving a different set of GI values (if white bread = 100, then glucose ≈ 140).

[Old Liberals] used the natural discontent of the people with the poverty and precariousness of the means of subsistence as a motive power to win for them a better, more influential, and more honourable status in the citizenship of their native land. The new Liberalism, while pursuing this great political ideal with unflinching energy, devotes a part of its endeavour also to the removing of the immediate causes of discontent. It is true that man cannot live by bread alone. It is equally true that a man cannot live without bread.

Sources: en.wikipedia.org

Reference notes

Alexios' concentration of power in the hands of his Komnenos dynasty meant the most serious political threats came from within the imperial family—before his coronation, John II had to overcome his mother Irene and his sister Anna, and the primary threat during his reign was his brother Isaac. John campaigned annually and extensively—he fought the Pechenegs in 1122, the Hungarians in the late 1120s, and the Seljuks throughout his reign, waging large campaigns in Syria in his final years—but he did not achieve large territorial gains. In 1138, John raised the imperial standard over the Crusader Principality of Antioch to intimidate the city into allying with the Byzantines, but did not attack, fearing that it would provoke western Christendom to respond. Manuel I used the considerable financial resources left by his father in pursuit of his ambitions, and also to secure the empire's position in an increasingly multilateral geopolitical landscape. Through a combination of diplomacy and subsidies, he cultivated a network of allies and client rulers around the empire: the Turks of the Sultanate of Rum, the Kingdom of Hungary, the Cilician Armenians, Balkan princes, Italian and Dalmatian cities, and most importantly Antioch and the Crusader States, marrying one of their princesses in 1161. Manuel managed the difficult passage of the Second Crusade through Byzantine territories in 1147, but the campaign's failure was blamed on the Byzantines by western contemporaries.

Although a further tiny energy gain could be extracted by synthesizing 62Ni, which has a marginally higher binding energy than 56Fe, conditions in stars are unsuitable for this process. Element production in supernovas greatly favor iron over nickel, and in any case, 56Fe still has a lower mass per nucleon than 62Ni due to its higher fraction of lighter protons. Hence, elements heavier than iron require a supernova for their formation, involving rapid neutron capture by starting 56Fe nuclei. In the far future of the universe, assuming that proton decay does not occur, cold fusion occurring via quantum tunnelling would cause the light nuclei in ordinary matter to fuse into 56Fe nuclei. Fission and alpha-particle emission would then make heavy nuclei decay into iron, converting all stellar-mass objects to cold spheres of pure iron.

The reference interval for normal BUN/creatinine serum ratio is 12 : 1 to 20 : 1. An elevated BUN:Cr due to a low or low-normal creatinine and a BUN within the reference range is unlikely to be of clinical significance.

Sources: en.wikipedia.org

Notes from published material

Sequence variation of Bemisia tabaci Chemosensory protein 2 in cryptic species B and Q: new DNA markers for whitefly recognition. Gene 2016a; 576: 284-291. 26. Zhu J, Wang G, Pelosi P. Plant transcriptomes reveal hidden guests. Biochem Biophys Res Commun. 2016; 474: 497-502. 27. Perkin LC, Friesen KS, Flinn PW, Oppert B. Venom gland components of the ectoparasitoid wasp, Anisopteromalus calandrae. J. Venom Res. 2015; 6: 19-37. 28. Celorio-Mancera MdP, Sundmalm SM, Vogel H, Rutishauser D, Ytterberg AJ, Zubarv RA et al. Chemosensory proteins, major salivary factors in caterpillar mandibular glands. Insect Biochem Mol Biol. 2012; 42: 796-805. 29. González-Caballero N, Valenzuela JG, Ribeiro JMC, Cuervo P, Brazil RP. Transcriptome exploration of the sex pheromone gland of Lutzomyia longipalpis (Diptera: Psychodidae: Phlebotominae). Parasit Vect. 2013; 6: 56. 30. Liu YL, Guo H, Huang LQ, Pelosi P, Wang CZ. Unique function of a chemosensory protein in the proboscis of two Helicoverpa species. J Exp Biol. 2014; 217: 1821-1826. 31. Zhu J, Iovinella I, Dani FR, Liu YL, Huang LQ, Liu Y, et al. Conserved chemosensory proteins in the proboscis and eyes of Lepidoptera. Int J Biol Sci. 2016; 12: 1394-1404. 32. Xuan N, Guo X, Xie HY, Lou QN, Bo LX, Liu GX, et al. Increased expression of CSP and CYP genes in adult silkworm females exposed to avermectins. Insect Sci. 2015; 22: 203-219. 33. Sabatier L, Jouanguy E, Dostert C, Zachary D, Dimarcq JL, Bulet P, et al.

water of crystallization Also water of hydration. Water molecules that are present inside crystals. Upon crystallization from water or aqueous solutions, many compounds incorporate water in the interstices of their crystalline frameworks; the water molecules are typically present in a stoichiometric ratio and may interact to varying degrees with the atoms of the crystal.

However, the importer of the wheat gluten, ChemNutra, claims that they received from Xuzhou Anying results of analyses showing "no impurities or contamination." It has not yet been determined whether Xuzhou Anying products other than wheat gluten have been shipped to North America. The second Chinese supplier involved in shipping melamine-contaminated food ingredients, Binzhou Futian Biology Technology, has been working with importer Wilbur-Ellis since July 2006. Binzhou Futian supplies soy, corn and other proteins to the United States, Europe and Southeast Asia. Binzhou typically ships rice protein concentrate in white bags but on 11 April one bag was pink and had the word "melamine" stenciled on it. Binzhou explained to Wilbur-Ellis that the original bag had broken and a mislabeled, but new, bag had been used. The company only supplies food and feed ingredients. Stephen Sundlof, director of the FDA's Center for Veterinary Medicine, said that melamine turning up in exported Chinese wheat gluten, rice protein concentrate and corn gluten supports theories of intentional adulteration. "That will be one of the theories we will pursue when we get into the plants in China." On 29 April 2007 and 30 April 2007, the International Herald Tribune and The New York Times reported that some animal feed manufacturers in China admit to having used melamine scrap in animal feed for years. Said Ji Denghui, general manager of the Fujian Sanming Dinghui Chemical Company: “Many companies buy melamine scrap to make animal feed, such as fish feed. I don't know if there’s a regulation on it.

== Seat projections == 326 seats are needed for a majority. The party with the most seats is shaded in its colour, and where a party reaches the majority threshold, in bold. The party with the second-most seats is shaded in grey. All polls so far have been conducted excluding the 18 seats in Northern Ireland. Multilevel regression with poststratification (MRP) is the most common methodology for projecting seats nationally. Multiple polling companies have conducted such polling and modelling for the next election, these are tabulated below. Also included are some polls compiled via Political Analysis through Regional and Local Insights System (POLARIS), a novel model created by JL Partners which uses council by-elections to predict election outcomes. POLARIS polls from January 2025 onwards are also combined with a representative survey data, with the data used shifted to reflect the pollster's most recent national polling.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Is BPC-157 approved for medical use?

No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.

Why is the literature on BPC-157 considered preliminary?

Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.

What is BPC-157 made of?

It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.

Network